Overview A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis Status: Terminated Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis. Phase: Phase 1 Details Lead Sponsor: Reata Pharmaceuticals, Inc.